Safer. Singlepass is a small, hand-held device that works seamlessly with the biopsy procedure as it fits with an 18 Gauge guide needle or larger.
Patented, Disposable, Electrocautery Device
The Singlepass biopsy closure cautery device is the only single-use tool for co-axial biopsies that uses a patented method of cauterizing damaged tissue to prevent bleeding. This means less adverse events and less time spent in the hospital.
Improves the biopsy
With more than 27 million new cases of cancer predicted to occur in the next 17 years, improving the biopsy experience is more important than ever.
Faster. The cauterization process is quick. The single-use, disposable tool has a probe tip that “heat-seals” the tissue damaged from the biopsy in a matter of minutes.
Effective. In two case studies of 60 patients with lung, liver, or kidney biopsies, Singlepass was used to prevent bleeding. There were zero adverse events and the biopsy channels were completely blood free every time.
As Featured In
Decreases anxiety and hold time
Bleeding after a biopsy is a common problem. But now, with Singlepass, your patients and staff have a solution.
-
Decrease risk Because this tool can go through a biopsy guide needle and poses no new threats to at-risk patients, they can directly benefit from the safe, effective procedure. This decreases anxiety in both patients and staff.
-
Shorten hospital stay. The four to eight hour hold time that is common practice after a biopsy is to watch for adverse events. This hold time can be shortened or eliminated altogether with the effective use of Singlepass.
-
Frees up beds. If holding time is eliminated or shortened, then nursing hours and beds are freed up. This can save thousands of dollars and build patient confidence.
-
May prevent seeding. Some medical professionals have suggested this procedure may prevent tumor seeding, which is when cancer cells spread after a biopsy.
-
Modern design. Singlepass uses two AA batteries in the handle to power the cauterization. Its light-weight design is user-friendly and disposable.
“The biopsy channels were completely blood free after cauterization with confirmation by multiple imaging modalities.
Our confidence for performing co-axial biopsy procedures without potential bleeding issues has increased.”
- Dainis Krievins, MD, PhD
In The Media
Articles & media covering the Single Pass device
Article
Single Pass Announces Receipt of CE Mark for its Biopsy Closure Device
CEO, Bill Colone, announced today that the company received the CE Mark under EU MDR
Article
Digital Journal Press Release: A Revolutionary Device
This device stands out in terms of speed and ease of use and currently has no direct competitors.
Article
Revolutionizing Healthcare with Innovative Biopsy Solutions
The core offering of SinglePass Inc. is a single-use disposable device meticulously designed to revolutionize biopsy procedures.
Article
Business Insider: Redefining Biopsy Procedures
At the heart of their mission is the unwavering commitment to preventing internal bleeding during diagnostic procedures, a goal that significantly improves...
Article
SinglePass Inc.’s Patented Device Redefines Biopsy Safety
In a remarkable stride towards improving healthcare, SinglePass, Inc. led by CEO Bill Colone, is redefining the way biopsy procedures are performed...
Article
SinglePass Inc.’s Patented Device Redefines Biopsy Safety
In a remarkable stride towards improving healthcare, SinglePass, Inc. led by CEO Bill Colone, is redefining the way biopsy procedures are performed...
Podcast
Podcast Interview with Jon Cobb, Founder & CEO of JON COBB Coaching
Journey to Empower Rising Leaders for Fulfillment and Success Join us today and understand more about his journey.
Podcast
Can a new electrocautery device revolutionize biopsies?
Every year, millions of people require organ biopsies to check whether the cells are cancerous or not. However, problems can arise when unintended bleeding occurs...
Article
Single Pass Announces Successful Initiation of Clinical Evaluation
Single Pass, Inc. CEO, Bill Colone, announced the initiation of the clinical evaluation for the Kronos Electrocautery device designed to improve...
Article
Single Pass Treats First Patients in North America
Said Dr. Tahour, "The Kronos Single Pass device produced excellent clinical results. It offers a breakthrough solution for patients undergoing percutaneous biopsy who are at high risk of bleeding complications.
Article
Guiding Success In Cauterizing Deep Tissue Biopsy
Percutaneous biopsy plays a crucial role in providing efficient, minimally invasive, and cost-effective diagnoses of malignancy and parenchymal diseases, particularly in solid organs such as the liver and kidney.
Article
Turning Doctors Ideas Into Business Products
Percutaneous biopsy plays a crucial role in providing efficient, minimally invasive, and cost-effective diagnoses of malignancy and parenchymal diseases, particularly in solid organs such as the liver and kidney.
Article
California hospital 1st in nation to use biopsy device
Long Beach (Calif.) Medical Center on Oct. 17 became the first facility in the nation to use a new biopsy device.
Podcast
Bill Colone: The One Thing
MedTech startups found themselves flush with cash a couple of years ago for quite obvious reasons. Pandemic-fuelled investment pushed VC funding for medtech and health-focused companies to unforeseen heights.
Meet our people
Our team has over 100 years of combined experience in medical technologies, more than 150 patents, and four successful medical device startups.
-
Bill Colone,
CEO, Singlepass
With over 30 years of experience with medical device development, Bill has a long history of listening to what physicians and surgeons say is needed to help them and their patients. He was the CEO of Endomed and Spinal Singularity, as well as the Director of R&D for Endologix and the VP of R&D for Direct Flow Medical. He holds 13 US patents.
-
Dave Ferrera
Board Member
Dave is currently serving as Managing Director at RC Medical, where he works with physicians to identify new devices for the medical community. He was CEO of Blockade Medical and Chief Technology Officer at Balt. Dave was also the co-founder, GM, and VP of Product Development/Clinical Research of Mindframe.
-
Peter Sunenshine
MD Chief of Neurointerventional Surgery, Banner University Medical Center
Before coming to Banner University Medical Center, Dr. Sunenshine completed a fellowship in Neurointerventional radiology at NYU and a radiology / neurology / neuroradiology residency at NYU Medical Center/Bellevue Medical Center. For the last 15 years, he has been a practicing Neuroradiologist / Neurointerventional radiologist. Dr. Sunenshine also serves as Clinical Assistant Professor at the University of Arizona College of Medicine-Phoenix.
-
Kevin Hirsch
MD Chairman Dept of Radiology, Banner University Medical Center
Dr. Hirsch specializes in Vascular and Interventional Radiology and serves as Interim Chair Department of Radiology, University of Arizona College of Medicine-Phoenix. He attended the University of Southern California/LAC-USC Medical Center for medical school, residency and fellowship. Dr. Hirsch has led a thriving radiology practice in Arizona for over 13 years.
Bill Colone presented SinglePass at LSI USA ‘23 Emerging Medtech Summit
Single Pass has developed a patented, battery-powered, disposable electrocautery device for cauterizing deep tissue biopsy channels after solid organ biopsy procedures.
We want to hear your thoughts.
Singlepass is small yet powerful. To talk about how it can save you and your patients time and money by preventing bleeding in co-axial biopsies, please complete this form. We want to hear from you